A detailed history of Parnassus Investments, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Parnassus Investments, LLC holds 873,001 shares of BMRN stock, worth $71.9 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
873,001
Previous 1,849,348 52.79%
Holding current value
$71.9 Million
Previous $178 Million 57.24%
% of portfolio
0.17%
Previous 0.41%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$83.81 - $99.0 $81.8 Million - $96.7 Million
-976,347 Reduced 52.79%
873,001 $76.2 Million
Q4 2023

Feb 12, 2024

SELL
$76.22 - $98.51 $37.3 Million - $48.2 Million
-489,181 Reduced 20.92%
1,849,348 $178 Million
Q4 2022

Jan 30, 2023

SELL
$80.93 - $108.63 $18.4 Million - $24.7 Million
-227,551 Reduced 8.87%
2,338,529 $242 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $17.7 Million - $20.9 Million
-215,340 Reduced 7.74%
2,566,080 $218 Million
Q2 2022

Aug 05, 2022

BUY
$71.48 - $86.85 $3.97 Million - $4.82 Million
55,490 Added 2.04%
2,781,420 $230 Million
Q4 2021

Feb 11, 2022

BUY
$71.72 - $91.47 $2.94 Million - $3.76 Million
41,056 Added 1.53%
2,725,930 $241 Million
Q1 2021

May 06, 2021

BUY
$74.73 - $90.69 $87.1 Million - $106 Million
1,165,923 Added 76.76%
2,684,874 $203 Million
Q4 2020

Feb 10, 2021

BUY
$72.61 - $90.2 $96.7 Million - $120 Million
1,331,882 Added 711.97%
1,518,951 $133 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $7 Million - $12.8 Million
97,349 Added 108.5%
187,069 $14.2 Million
Q2 2020

Aug 12, 2020

BUY
$79.55 - $124.22 $7.14 Million - $11.1 Million
89,720 New
89,720 $11.1 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $15.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Parnassus Investments, LLC Portfolio

Follow Parnassus Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parnassus Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parnassus Investments, LLC with notifications on news.